CamMEDICA develops products that prevent or halt the development of major health issues affecting large populations. The Company’s products are phytochemicals that are known to be safe and are thus suitable for long-term prophylactic use in generally healthy pre-disease individuals.
The Company was founded in 2006 and is privately held. It has a ‘network’ business model that leverages the capabilities of leading global partners. The products are protected by a series of the Company’s own patents and by an exclusive license to technology developed by Nestlé.
Intellectual property
CamMEDICA has 4 patents pending world-wide. In addition, it has a global, exclusive license to a technology developed by Nestlé .
CamMEDICA’s IP claims technologies, methods and nutritional, pharmaceutical preparations directed to intervention in and prevention of metabolic syndrome and pre-diabetes.
Launch of Laflavon™ to treat
‘metabolic syndrome’
CamMEDICA plans to launch its first product Laflavon™, early in 2010.